Annual Report 2022

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2022 155 The United Laboratories International Holdings Limited Annual Report 2022 Name of subsidiaries Place of incorporation/ establishment Issued and fully paid share capital/ registered capital Attributable equity interest held by the Company Principal activities and place of operation (Note a) 2022 2021 成都智匯城有限公司 (Note c) The PRC RMB10,000,000 100% 100% Investment holding in the PRC The United Bio-Technology (Hengqin) Co., Ltd (Note c) The PRC RMB100,000,000 100% 100% Research and development of pharmaceutical products in the PRC 珠海聯邦生物醫藥有限公司 (Note c) The PRC RMB100,000,000 100% 100% Research and development of pharmaceutical products in the PRC 河南聯牧獸藥有限公司 (Note e) The PRC RMB50,000,000 60% N/A Manufacturing and sale of pharmaceutical products the PRC Notes: (a) Other than The United Laboratories (Hong Kong) Holding Limited, all subsidiaries are indirectly held by the Company. (b) A wholly foreign-owned enterprise established in the PRC. (c) A company established in the PRC with limited liability. (d) A joint stock limited liability company established in the PRC. (e) A company established in the PRC with limited liability during the year ended 31 December 2022. 44. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY (Continued)